ATE232097T1 - Verwendung von sulfaminsäuren derivaten, acrylsulfonamiden oder sulfonylcarbonaten zur herstellung eines arzneimittels zur senkung des spiegels von lipoproteinen - Google Patents

Verwendung von sulfaminsäuren derivaten, acrylsulfonamiden oder sulfonylcarbonaten zur herstellung eines arzneimittels zur senkung des spiegels von lipoproteinen

Info

Publication number
ATE232097T1
ATE232097T1 AT96923687T AT96923687T ATE232097T1 AT E232097 T1 ATE232097 T1 AT E232097T1 AT 96923687 T AT96923687 T AT 96923687T AT 96923687 T AT96923687 T AT 96923687T AT E232097 T1 ATE232097 T1 AT E232097T1
Authority
AT
Austria
Prior art keywords
pct
sulfonylcarbonates
acrylsulfonamides
lipoproteins
lowering
Prior art date
Application number
AT96923687T
Other languages
English (en)
Inventor
Brian Robert Krause
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Application granted granted Critical
Publication of ATE232097T1 publication Critical patent/ATE232097T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96923687T 1995-08-04 1996-07-08 Verwendung von sulfaminsäuren derivaten, acrylsulfonamiden oder sulfonylcarbonaten zur herstellung eines arzneimittels zur senkung des spiegels von lipoproteinen ATE232097T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US303195P 1995-08-04 1995-08-04
PCT/US1996/011366 WO1997005868A1 (en) 1995-08-04 1996-07-08 Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels

Publications (1)

Publication Number Publication Date
ATE232097T1 true ATE232097T1 (de) 2003-02-15

Family

ID=21703764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96923687T ATE232097T1 (de) 1995-08-04 1996-07-08 Verwendung von sulfaminsäuren derivaten, acrylsulfonamiden oder sulfonylcarbonaten zur herstellung eines arzneimittels zur senkung des spiegels von lipoproteinen

Country Status (27)

Country Link
US (1) US6117909A (de)
EP (1) EP0841913B1 (de)
JP (1) JPH11510184A (de)
KR (1) KR19990036127A (de)
CN (1) CN1192140A (de)
AT (1) ATE232097T1 (de)
AU (1) AU716255B2 (de)
BG (1) BG63863B1 (de)
CA (1) CA2221729A1 (de)
CZ (1) CZ26198A3 (de)
DE (1) DE69626118T2 (de)
DK (1) DK0841913T3 (de)
EA (1) EA002435B1 (de)
EE (1) EE9800037A (de)
ES (1) ES2191762T3 (de)
GE (1) GEP20012511B (de)
HR (1) HRP960341A2 (de)
HU (1) HUP9900668A3 (de)
IL (1) IL122247A0 (de)
NO (1) NO980466D0 (de)
NZ (1) NZ312571A (de)
PL (1) PL185943B1 (de)
PT (1) PT841913E (de)
SK (1) SK12598A3 (de)
UA (1) UA46030C2 (de)
WO (1) WO1997005868A1 (de)
ZA (1) ZA966617B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1584333A3 (de) * 1998-01-28 2009-04-29 Warner-Lambert Company LLC Verwendung von Acetylcoenzyme A Inhibitoren zur Behandlung von Alzheimer
KR20010083134A (ko) * 1998-07-21 2001-08-31 로즈 암스트롱, 크리스틴 에이. 트러트웨인 아테롬성 동맥경화증 병소의 치료를 위한 acat 및mmp 억제제의 병용 투여
IT1303249B1 (it) * 1998-10-23 2000-11-06 Dompe Spa Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono.
CN1414848A (zh) * 1999-11-05 2003-04-30 沃尼尔·朗伯公司 Acat抑制剂对斑块破裂的预防
CA2369967A1 (en) * 2001-02-12 2002-08-12 Joseph Anthony Cornicelli Methods of treating nuclear factor-kappa b mediated diseases and disorders
AR037097A1 (es) 2001-10-05 2004-10-20 Novartis Ag Compuestos acilsulfonamidas, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
US6939224B2 (en) * 2002-03-12 2005-09-06 Igt Gaming device having varying risk player selections
CN111344287B (zh) 2017-11-14 2023-12-19 默沙东有限责任公司 作为吲哚胺2,3-双加氧酶(ido)抑制剂的新型取代的联芳基化合物
US11498904B2 (en) 2017-11-14 2022-11-15 Merck Sharp & Dohme Llc Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5003106A (en) * 1983-07-19 1991-03-26 American Cyanamid Company Antiatherosclerotic ureas and thioureas
EP0555351B1 (de) * 1990-10-30 1994-12-28 Warner-Lambert Company Oxysulfonylcarbamate
US5245068A (en) * 1990-10-30 1993-09-14 Warner-Lambert Company Oxysulfonyl carbamates
IL101785A0 (en) * 1991-05-10 1992-12-30 Fujisawa Pharmaceutical Co Urea derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en) * 1993-05-14 2001-01-11 Warner Lambert Co Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds

Also Published As

Publication number Publication date
IL122247A0 (en) 1998-04-05
GEP20012511B (en) 2001-08-27
DE69626118T2 (de) 2003-11-27
CN1192140A (zh) 1998-09-02
NO980466L (no) 1998-02-03
EP0841913A1 (de) 1998-05-20
EE9800037A (et) 1998-08-17
HUP9900668A2 (hu) 1999-06-28
ES2191762T3 (es) 2003-09-16
ZA966617B (en) 1997-02-18
SK12598A3 (en) 1999-02-11
NZ312571A (en) 2000-07-28
US6117909A (en) 2000-09-12
DE69626118D1 (de) 2003-03-13
UA46030C2 (uk) 2002-05-15
PL324908A1 (en) 1998-06-22
KR19990036127A (ko) 1999-05-25
NO980466D0 (no) 1998-02-03
CZ26198A3 (cs) 1998-07-15
EA002435B1 (ru) 2002-04-25
PT841913E (pt) 2003-06-30
CA2221729A1 (en) 1997-02-20
HUP9900668A3 (en) 2000-08-28
WO1997005868A1 (en) 1997-02-20
AU6454196A (en) 1997-03-05
DK0841913T3 (da) 2003-05-05
AU716255B2 (en) 2000-02-24
BG63863B1 (bg) 2003-04-30
EP0841913B1 (de) 2003-02-05
HRP960341A2 (en) 1998-02-28
BG102222A (en) 1998-09-30
EA199800176A1 (ru) 1998-10-29
PL185943B1 (pl) 2003-09-30
JPH11510184A (ja) 1999-09-07

Similar Documents

Publication Publication Date Title
ATE242213T1 (de) Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
DE69629184D1 (de) Verwendung von vitamin d2 oder vitamin d4-derivaten zur herstellung eines medikamentes zur behandlung des sekundären hyperparathyroidismus
DE60019904D1 (de) Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
DE69201948D1 (de) Verwendung von 1,3-oxathiolanalogen von nukleosiden zur herstellung eines arzneimittels zur behandlung von hepatitis-b.
DE69515038T2 (de) Verwendung von raloxifen und dessen analogen zur herstellung eines medikaments zur behandlung viraler erkrankungen
ATE268752T1 (de) Aralkyl-1,2-diaminen mit calcimimetischer wirkung und verfahren zu ihrer herstellung
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE232097T1 (de) Verwendung von sulfaminsäuren derivaten, acrylsulfonamiden oder sulfonylcarbonaten zur herstellung eines arzneimittels zur senkung des spiegels von lipoproteinen
DE3888340D1 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
DE69420832D1 (de) Die Verwendung von Carbostyrilderivaten zur Herstellung eines Arzneimittels zur Hemmung der Produktion von Interleukin-8
DE69501359T2 (de) Verwendung von Phosphatdiestern zur Behandlung von Erkrankungen der Retina
ATE196080T1 (de) Verwendung von diphenylethanderivaten zur herstellung eines arzneimittels zur behandlung von glaukom
DE69606777D1 (de) Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel
DE69616357T2 (de) Benzocycloalken-verbindungen mit bindungsaffinität an den melatonin-rezeptor, ihre herstellung und verwendung
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
MX9709275A (es) Uso de los derivados del acido sulfamico, carbamatos acil sulfonamidas o sulfonil para la manufactura de un medicamento para disminuir los niveles de lipoproteinas.
DE69421705D1 (de) Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
ATE192650T1 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
ATE7298T1 (de) Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel.
ATE173921T1 (de) Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
ATE263565T1 (de) Verwendung von 8,9-dehydroestron zur herstellung eines arzneimittels zur behandlung von durch freie radikale verursachte krankheiten
DE69629188D1 (de) Verwendung von (r)-penciclovirtriphosphat zur herstellung eines arzneimittels zur behandlung von viruserkrankungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0841913

Country of ref document: EP

REN Ceased due to non-payment of the annual fee